For research use only. Not for therapeutic Use.
UTL-5g(Cat No.:I037899), also known as GBL-5g, is an anti-inflammatory inhibitor of TNF-α (tumor necrosis factor-alpha) that demonstrates chemoprotective and hepatic radioprotective effects. It effectively reduces the hepatotoxicity, nephrotoxicity, and bone marrow toxicity associated with cisplatin by inhibiting TNF-α and other related factors. By modulating the inflammatory response, UTL-5g shows the potential in mitigating the adverse effects of cisplatin treatment.
Catalog Number | I037899 |
CAS Number | 646530-37-2 |
Synonyms | UTL-5g; UTL 5g; UTL5g; |
Molecular Formula | C11H8Cl2N2O2 |
Purity | 98% |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
IUPAC Name | N-(2,4-dichlorophenyl)-5-methyl-1,2-oxazole-3-carboxamide |
InChI | InChI=1S/C11H8Cl2N2O2/c1-6-4-10(15-17-6)11(16)14-9-3-2-7(12)5-8(9)13/h2-5H,1H3,(H,14,16) |
InChIKey | ULPKSWAQDCJLMN-UHFFFAOYSA-N |
SMILES | CC1=CC(=NO1)C(=O)NC2=C(C=C(C=C2)Cl)Cl |
Reference | 1: Carruthers NJ, Stemmer PM, Chen B, Valeriote F, Gao X, Guatam SC, Shaw J. Phosphoproteome and transcription factor activity profiling identify actions of the anti-inflammatory agent UTL-5g in LPS stimulated RAW 264.7 cells including disrupting actin remodeling and STAT-3 activation. Eur J Pharmacol. 2017 Sep 15;811:66-73. doi: 10.1016/j.ejphar.2017.05.049. Epub 2017 May 31. PubMed PMID: 28576409; PubMed Central PMCID: PMC5581996. |